Regulatory Focus™ > News Articles > Follow-on Biologics in the EU & US

Follow-on Biologics in the EU & US

Posted 01 January 2008 | By

Global regulatory agencies are working hard to facilitate bringing copies of well-known medicinal biologics to market. Three key factors drive this process:

  • technological advancements permitting better characterization and testing of protein-based biologic products
  • patent expiration on many biologics in the EU and US
  • escalating healthcare costs

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe